An Immune Evading Vectors for Treating Genetic Diseases

Time: 8:30 am
day: Day Two


  • Review of current safety challenges facing AAV based gene therapies
  • Introducing the EVADER platform, which results in products that are more potent and less immunogenic
  • Exploring the advantages for treating genetic diseases affecting muscle cells